Drug Database
Back to search

Switzerland· 69039003

Beyfortus 100 mg/1 ml, solution injectable en seringue préremplie

A nirsevimab product containing nirsevimabum, registered in Switzerland by Sanofi-Aventis (Suisse) SA and dispensed under Swissmedic category A. The same ATC class is registered in 14 of our 19 countries.

Cat A (Swissmedic)ATC J06BD08

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedBeyfortus 100 mg/1 ml, solution injec…ATCJ06BD08REGISTER NO.69039003PACKS LISTED0CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about nirsevimabumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Nirsevimab is registered in 14 of 19 countries.

Countries holding a registration under ATC J06BD08 (nirsevimab), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 9 of them publish a price we can compare per daily dose
Search nirsevimab products by name

Nirsevimab · ATC J06BD08

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Swissmedic (Switzerland)
Active substance
nirsevimabum
Manufacturer
Sanofi-Aventis (Suisse) SA
Country
Switzerland (CH)
ATC code
J06BD08
ATC class
Nirsevimab
Swissmedic category
A
Reimbursed
No
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Nirsevimab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All nirsevimab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Beyfortus
  • Liechtenstein · Beyfortus
  • Norway · Beyfortus

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e8172763-c8a4-4d62-909c-f6852baa62cd
GET /v1/drugs/e8172763-c8a4-4d62-909c-f6852baa62cd?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{}
API referenceMCP serverPlans

See everything about nirsevimab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console